To explore concordance across tumor and blood p16 measurements and whether CK+ CTCs are an adequate surrogate for tumor in PD assessments of FdCyd-associated changes in p16 expression, we compared CTC p16 expression changes with treatment-induced modulation of tumor p16 expression and CDKN2A hypomethylation. The gene discussed is CDKN2A; the disease is neoplasm.